Cargando…
20. Risk Factors for Breakthrough Cytomegalovirus (CMV) Infection and De Novo Resistance in Hematopoietic Cell Transplantation (HCT) Recipients Receiving Letermovir Prophylaxis
BACKGROUND: Subclinical CMV reactivation on letermovir prophylaxis may be important for CMV-specific immune reconstitution after HCT (Zamora et al. Blood 2021) but concerns remain regarding the development of antiviral resistance. Here we analyze risk factors associated with breakthrough CMV infecti...
Autores principales: | Zamora, Danniel, Perchetti, Garrett, Biernacki, Melinda, Xie, Hu, Castor, Jared L, Joncas-schronce, Laurel, Blazevic, Rachel, Leisenring, Wendy, Huang, Meei-Li, Jerome, Keith, Martin, Paul J, Boeckh, Michael, Greninger, Alexander L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643935/ http://dx.doi.org/10.1093/ofid/ofab466.020 |
Ejemplares similares
-
491. Characterizing the Association of Pre-Existing Cytomegalovirus (CMV)-specific Humoral Immunity with CMV Reactivation Risk after Hematopoietic Cell Transplantation (HCT)
por: Zamora, Danniel, et al.
Publicado: (2022) -
2591. The Role of Neutralizing Antibodies (nAb) Against Cytomegalovirus (CMV) Epithelial Cell-entry in Patients with Self-limited (SL) CMV infection after Hematopoietic Cell Transplantation (HCT)
por: Zamora, Danniel, et al.
Publicado: (2019) -
1751. The Impact of Prophylactic Systemic Antibiotics (PSA) on Cytomegalovirus (CMV) Infection: A Post-hoc Analysis of a Randomized Controlled Trial (RCT) in Hematopoietic Cell Transplantation (HCT) Recipients
por: Zamora, Danniel, et al.
Publicado: (2019) -
A Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT)
por: Maertens, Johan, et al.
Publicado: (2017) -
2109. HHV-6 and EBV Reactivation after Allogeneic Hematopoietic Cell Transplantation in the Era of Letermovir for CMV Prophylaxis: A Retrospective Cohort Study
por: Kampouri, Eleftheria, et al.
Publicado: (2022)